Browse Non-Hodgkin's lymphomas topic

Drug therapy subtopic

Articles 1-47 out of 47 article(s) Title Author Type Date Words Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. Dec 8, 2009 901 ISTODAX[R] Incorporated Into NCCN Clinical Practice Guidelines in Oncology[TM] for the Treatment of Cutaneous T-cell Lymphoma (CTCL). Dec 3, 2009 907 Allos Therapeutics Announces U.S. Availability of FOLOTYN[TM] (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma. Oct 5, 2009 980 Allos Therapeutics' FOLOTYN[TM] First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma. Sep 25, 2009 1884 United States : Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin s Lymphoma. Sep 5, 2009 290 United States : FDA OKs Spectrum s Zevalin as blood-cancer treatment. Sep 5, 2009 249 United States : FDA Approves Ibritumomab Tiuxetanton as First-Line Therapy for Non-Hodgkin's Lymphoma. Sep 5, 2009 161 FDA Approves ZEVALIN[R] Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin's Lymphoma. Sep 4, 2009 1535 Gloucester Pharmaceuticals Announces FDA Advisory Committee Meeting to Discuss Romidepsin New Drug Application. Aug 17, 2009 335 Research and Markets: Lymphoma Drug Development Strategies at Work: New Report Includes Defined and Up to Date Development Strategies for 176 Lymphoma Therapeutic Drugs. Jul 17, 2009 380 Personalized Anti-Cancer Vaccine, BiovaxID[R], Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis. Clinical report Jun 28, 2009 1692 Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID[R], Presented at ASCO Plenary Session. Clinical report May 31, 2009 1721 Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Mar 25, 2009 1730 Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission. Mar 17, 2009 1069 FDA Approves Genzyme's Mozobil. Dec 15, 2008 1620 FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS LYMPHOMA. Dec 1, 2008 1022 U.S. FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Nov 24, 2008 900 FDA Grants Full Approval to ONTAK' (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL). Oct 16, 2008 539 Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%. Oct 7, 2008 2298 WALES: Cancer charity hails drug success. Aug 16, 2008 183 Returning home to care for a dying mother: a nurse spends ten months caring for her dying mother at home. Though an incredibly difficult and painful experience, she believes it has made her a better, more empathetic nurse. Polglaze, Tracey Aug 1, 2008 2983 Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results. Jul 21, 2008 838 Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial. Financial report Jul 17, 2008 1194 Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms. Jun 11, 2008 812 Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R). Apr 17, 2008 1539 Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma. Apr 17, 2008 2101 Cancer drug hopes. Feb 28, 2008 177 InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin's Lymphoma With Leading Marketed Product. Feb 7, 2008 712 Uptake of Rituxan in the Maintenance Setting for Follicular Lymphoma (FL) Has Allowed the Drug to Achieve Further Market Penetration. Feb 1, 2008 436 Examine Detailed Information on the Current Non-Hodgkin Lymphoma Drug Pipeline with This New Report. Report Aug 23, 2007 372 NHS arthritis patients will get drug that f ights cancer; Pain: The disease inflames the joints. Aug 22, 2007 595 NHS arthritis patients will get drug that fights cancer; Pain: The disease inflames the joints. Aug 22, 2007 591 Worcester biotech company to seek approval of cancer drug. Jun 6, 2007 399 Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma. Apr 30, 2007 795 Seattle Genetics Initiates Phase II Clinical Trial of SGN-40 for the Treatment of Non-Hodgkin's Lymphoma. Dec 20, 2006 654 Accentia Biopharmaceuticals Majority-Owned Subsidiary Receives Rare Disease Designation from European Drug Agency for Follicular non-Hodgkin's Lymphoma. Oct 11, 2006 820 FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies. Oct 9, 2006 8330 FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies. Oct 7, 2006 8330 FDA Grants Biovest International Fast Track Status for BiovaxID(TM); Personalized Vaccine for Follicular Non-Hodgkin's Lymphoma Receives Fast Track Status from FDA. May 11, 2006 906 FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM); Personalized Vaccine for Follicular Non-Hodgkin's Lymphoma Receives Fast Track Status from FDA. May 11, 2006 916 FDA ruling awaited on use of cancer drug for arthritis. Feb 9, 2006 263 Tuberculosis mimicking Kikuchi's disease. Chakravarthy, Yeshwanth Feb 1, 2006 1109 BiovaxID(TM), Personalized Anti-Cancer Vaccine from Biovest International, Produces Long Term Clinical Remission and 95 Percent Overall Survival in Patients with Follicular Non-Hodgkin's Lymphoma in Phase 2 Clinical Trial. Jan 10, 2006 1064 Taking on a lethal blood cancer. Seppa, Nathan Brief Article Jan 1, 2005 151 Idec's Zevalin wins euro nod. Webb, Marion Brief Article Oct 6, 2003 80 Amgen Buys Cancer Drug. Dec 25, 2000 107 Results favorable for B-cell non-Hodgkin's lymphoma. Nov 1, 1998 190